Oncoinfo· @Oncoinfo_it · X·· 14 小时前评分70
正文 · 原文
#ESMO26 | Armando Orlandi commenta i risultati dello studio TALENT su T-DXd nelle pazienti con carcinoma mammario HR+/HER2-low in fase neoadiuvante👇
#OncoSTEPS #earlybreastcancer #eBC
40 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Oncoinfo · x.com